High Court Won't Review Case Over Skelaxin Antitrust Standing
The U.S. Supreme Court on Monday refused SigmaPharm Inc.'s bid to revive its lawsuit over royalties for a proposed generic version of prescription muscle relaxant Skelaxin, declining to review a rule...To view the full article, register now.
Already a subscriber? Click here to view full article